

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



偉俊生物科技有限公司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

PROFIT WARNING

This announcement is made by Wai Chun Bio-Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on preliminary assessment of the unaudited consolidated management accounts of the Company for the year ended 30 June 2024 (the “**Year**”) and the information currently available, the Group is expected to record a consolidated net loss for the Year ranging from approximately HK\$57.0 million to HK\$62.0 million as compared with the consolidated net loss of approximately HK\$10.0 million for the year ended 30 June 2023. The expected increase in the consolidated net loss for the Year was mainly due to, among other things, the decrease in gross profit of approximately HK\$16.2 million and impairment loss recognised on property, plant and equipment of approximately HK\$51.8 million.

The Company is still in the process of finalising the consolidated results of the Company for the Year. The information contained in this announcement can only be treated as a preliminary assessment by the Board based on the latest unaudited consolidated management accounts of the Company, which is subject to adjustments or amendments (if any), and the information currently available, and is not based on any figures nor information that has been audited, confirmed and/or reviewed by the auditor of the Company. Shareholders and potential investors of the Company are advised to read the annual results announcement of the Company for the Year which is expected to be published on 20 December 2024.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Wai Chun Bio-Technology Limited
Lam Ka Chun

Chairman, Chief Executive Officer and Executive Director

Hong Kong, 16 December 2024

As at the date of this announcement, the Board consists of one executive Director, namely Mr. Lam Ka Chun (Chairman and Chief Executive Officer) and three independent non-executive Directors, namely Mr. Wan Bo, Mr. He Tao and Ms. Kung Ying Tung.